Want to see DE:FYB full AI Analyst Report?
Formycon AG (FYB) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Fyb201 0.5 Mg (0.05 Ml Of 10 Mg/Ml) | Age-Related Macular Degeneration, Branch Retinal Vein Occlusion With Macular Edema, Central Retinal Vein Occlusion With Macular Edema | Phase IV | Completed | Ocular Safety and Usability Study for FYB201 PFS | Nov 25, 2024 | ― |
| Fyb203 2 Mg (0.05 Ml Of 40 Mg/Ml) | Diabetic Macular Edema, Age-Related Macular Degeneration, Diabetic Retinopathy, Branch Retinal Vein Occlusion With Macular Edema, Central Retinal Vein Occlusion With Macular Edema | Phase IV | Completed | Ocular Safety and Usability Study for FYB203 PFS | Nov 25, 2024 | ― |
| Fyb206, Keytruda | Non-Squamous Non-Small Cell Lung Cancer, Non Small Cell Lung Cancer | Phase III | Terminated | Similar Efficacy, Safety, and Immunogenicity of FYB206 in Comparison to Keytruda as add-on to Chemotherapy in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) | Oct 13, 2024 | ― |
| Fyb206, Keytruda | Melanoma Stage Iii, Melanoma, Stage Ii | Phase I | Active Not Recruiting | Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients | Aug 09, 2024 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Fyb201 0.5 Mg (0.05 Ml Of 10 Mg/Ml) | Phase IV | Age-Related Macular Degeneration, Branch Retinal Vein Occlusion With Macular Edema, Central Retinal Vein Occlusion With Macular Edema | Completed | Ocular Safety and Usability Study for FYB201 PFS | Nov 25, 2024 | ― |
| Fyb203 2 Mg (0.05 Ml Of 40 Mg/Ml) | Phase IV | Diabetic Macular Edema, Age-Related Macular Degeneration, Diabetic Retinopathy, Branch Retinal Vein Occlusion With Macular Edema, Central Retinal Vein Occlusion With Macular Edema | Completed | Ocular Safety and Usability Study for FYB203 PFS | Nov 25, 2024 | ― |
| Fyb206, Keytruda | Phase III | Non-Squamous Non-Small Cell Lung Cancer, Non Small Cell Lung Cancer | Terminated | Similar Efficacy, Safety, and Immunogenicity of FYB206 in Comparison to Keytruda as add-on to Chemotherapy in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) | Oct 13, 2024 | ― |
| Fyb206, Keytruda | Phase I | Melanoma Stage Iii, Melanoma, Stage Ii | Active Not Recruiting | Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients | Aug 09, 2024 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Formycon AG (DE:FYB) have in its pipeline
Formycon AG DE:FYB is currently developing the following drugs: Fyb201 0.5 Mg (0.05 Ml Of 10 Mg/Ml), Fyb203 2 Mg (0.05 Ml Of 40 Mg/Ml), Fyb206, Keytruda. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
